CytomX Therapeutics IPO Research Information

CytomX Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on CytomX Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
CytomX Therapeutics	CTMX - NASDAQ	$14.00-$16.00	$12.00	$16.00	6.7 million	10/8/2015
Underwriter(s): BofA Merrill Lynch, Jefferies, Cowen & Co.
Co-Manager(s): Oppenheimer & Co.
Industry: Health Care
Filing(s): Filed 2015-08-28 Terms Added 2015-09-28

CytomX Therapeutics Quote & Chart - Click for current quote - CTMX

About CytomX Therapeutics (adapted from CytomX Therapeutics prospectus):
They are an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on our Probody technology platform.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "CTMX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.